Brief Title: Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

• Urothelial Carcinoma

ELIGIBILITY

Inclusion Criteria:
* Adults > 18 years

- * Diagnosis of UTUC as determined by upper tract biopsy (either low or high grade)

- * Planned for nephroureterectomy by their urologic surgeon

- * Disease that is ≤cT4, N0M0. Participants must have complete TNM staging prior to surgery. cT disease can be determined by biopsy of the mass (if biopsy was deep enough) or imaging (CT/MRI). cN and cM stage must be determined by preoperative imaging of the chest, abdomen and pelvis.

- * No concomitant muscle-invasive bladder cancer

- * Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
* Pathologically enlarged lymph nodes suspicious for metastases which would require lymph node dissection regardless of trial (>cN0)

- * Presence of distant metastases

- * Concomitant muscle invasive bladder cancer

- * The participant is in a reduced general condition or has a life-threatening disease.

- * The participant has a psychiatric disorder that precludes them from understanding the consent process.

Gender: All

Minimum Age: 19 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Mohamed Eltemamy, MD, Adam Calaway, MD, MPH

Role: Principal Investigator, Principal Investigator

Affiliation: Cleveland Clinic, Glickman Urological and Kidney Institute, Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Urology Institute, Case Comprehensive Cancer Center

Overall Contact

Name: Mohamed Eltemamy, MD, Rebecca Campbell, MD

Phone: 216-444-5888, 216-444-1105

Email: Eltemam@ccf.org, CAMPBER7@ccf.org

LOCATION